Nuvation Bio (NYSE:NUVB) vs. BioLineRx (NASDAQ:BLRX) Head-To-Head Comparison

Nuvation Bio (NYSE:NUVB) and BioLineRx (NASDAQ:BLRX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Nuvation Bio and BioLineRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
BioLineRx	-502.08%	-34.80%	-18.27%

Earnings and Valuation

This table compares Nuvation Bio and BioLineRx”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90 million	32.24	-$204.63 million	($0.44)	-13.12
BioLineRx	$1.18 million	10.41	-$1.17 million	($1.69)	-1.50

BioLineRx has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Comparatively, 1.1% of BioLineRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Nuvation Bio and BioLineRx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1	2	10	0	2.69
BioLineRx	1	0	0	0	1.00

Nuvation Bio currently has a consensus price target of $13.00, indicating a potential upside of 125.11%. Given Nuvation Bio’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Nuvation Bio is more favorable than BioLineRx.

Volatility and Risk

Nuvation Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500.

Summary

Nuvation Bio beats BioLineRx on 9 of the 14 factors compared between the two stocks.

About Nuvation Bio

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.